We use cookies to enhance your browsing experience and analyze site traffic. By continuing to use this site, you agree to our cookie policy. Privacy Policy

News

Stay updated on Click.mAb. news, technology progress, and industry insights

Candidate Antibodies May Look Promising but Still Carry Developability Risks
Platform Updates
August 19, 2026

Candidate Antibodies May Look Promising but Still Carry Developability Risks

As candidate pools grow, the real question becomes which candidates are worth advancing. Click.mAb. now offers candidate list management and five-dimensional developability risk analysis, helping R&D teams centralize candidate sequences and assess potential risks across aggregation, chemical modification, humanness, polyreactivity, and viscosity to support candidate selection and optimization decisions.

Read Full Article
Clickmab at the 2026 Biophysics Congress: Sharing New Explorations in Epitope-Specific AI De Novo Antibody Design
Events
August 5, 2026

Clickmab at the 2026 Biophysics Congress: Sharing New Explorations in Epitope-Specific AI De Novo Antibody Design

The 2026 Biophysics Congress was recently held in Hainan, where Clickmab presented its proprietary Click.mAb. AI antibody R&D platform and shared its technical explorations in epitope-specific de novo design, affinity maturation, and humanization. During the congress, Zhang Hong, academician of the Chinese Academy of Sciences and president of the Chinese Biophysical Society, visited Clickmab's booth for an in-depth exchange.

Read Full Article
Academic Exchange | Visit to Hangzhou Institute of Medicine Chinese Academy of Sciences: Exploring New Frontiers in AI Antibody Design
Events
July 23, 2026

Academic Exchange | Visit to Hangzhou Institute of Medicine Chinese Academy of Sciences: Exploring New Frontiers in AI Antibody Design

Recently, Dr. Tianyuan Wang, CEO of Clickmab, conducted a special exchange session at the Hangzhou Institute of Medicine Chinese Academy of Sciences, delivering a keynote titled "Epitope-Specific AI De Novo Antibody Design for Antibody Drug R&D — Technical Principles, Current Applications, and Breakthrough Strategies." He shared the latest explorations of AI in antibody drug R&D and engaged in in-depth discussions with researchers on new trends, methods, and practical applications of AI-empowered biomedical R&D.

Read Full Article

Shape the Future of Antibody Therapeutics Together

Clickmab is dedicated to empowering antibody discovery through generative AI and welcomes partners across the ecosystem.

Get Started Contact Us